BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 22985796)

  • 1. CUB and zona pellucida-like domain-containing protein 1 (CUZD1): a novel serological biomarker for ovarian cancer.
    Leung F; Soosaipillai A; Kulasingam V; Diamandis EP
    Clin Biochem; 2012 Dec; 45(18):1543-6. PubMed ID: 22985796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Editorial comment on Leung et al.: CUB and zona pellucida-like domain-containing protein 1 (CUZD1): a novel serological biomarker for ovarian cancer.
    Hirte H
    Clin Biochem; 2012 Dec; 45(18):1547. PubMed ID: 23200087
    [No Abstract]   [Full Text] [Related]  

  • 3. False biomarker discovery due to reactivity of a commercial ELISA for CUZD1 with cancer antigen CA125.
    Prassas I; Brinc D; Farkona S; Leung F; Dimitromanolakis A; Chrystoja CC; Brand R; Kulasingam V; Blasutig IM; Diamandis EP
    Clin Chem; 2014 Feb; 60(2):381-8. PubMed ID: 24097894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients.
    Leung F; Dimitromanolakis A; Kobayashi H; Diamandis EP; Kulasingam V
    Clin Biochem; 2013 Oct; 46(15):1462-8. PubMed ID: 23528302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CUZD1 and anti-CUZD1 antibodies as markers of cancer and inflammatory bowel diseases.
    Liaskos C; Rigopoulou EI; Orfanidou T; Bogdanos DP; Papandreou CN
    Clin Dev Immunol; 2013; 2013():968041. PubMed ID: 23710207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrantly high expression of the CUB and zona pellucida-like domain-containing protein 1 (CUZD1) in mammary epithelium leads to breast tumorigenesis.
    Mapes J; Anandan L; Li Q; Neff A; Clevenger CV; Bagchi IC; Bagchi MK
    J Biol Chem; 2018 Feb; 293(8):2850-2864. PubMed ID: 29321207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Better Predictive Value of Cancer Antigen125 (CA125) as Biomarker in Ovary and Breast Tumors and its Correlation with the Histopathological Type/Grade of the Disease.
    Nazmeen A; Maiti S; Mandal K; Roy SK; Ghosh TK; Sinha NK; Mandal K
    Med Chem; 2017; 13(8):796-804. PubMed ID: 28440189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel immunoassays for detection of CUZD1 autoantibodies in serum of patients with inflammatory bowel diseases.
    Farkona S; Soosaipillai A; Filippou P; Liaskos C; Bogdanos DP; Diamandis EP; Blasutig IM
    Clin Chem Lab Med; 2017 Aug; 55(10):1574-1581. PubMed ID: 28343172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma miR-200b in ovarian carcinoma patients: distinct pattern of pre/post-treatment variation compared to CA-125 and potential for prediction of progression-free survival.
    Kapetanakis NI; Uzan C; Jimenez-Pailhes AS; Gouy S; Bentivegna E; Morice P; Caron O; Gourzones-Dmitriev C; Le Teuff G; Busson P
    Oncotarget; 2015 Nov; 6(34):36815-24. PubMed ID: 26416421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
    Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
    PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer.
    Leung F; Bernardini MQ; Brown MD; Zheng Y; Molina R; Bast RC; Davis G; Serra S; Diamandis EP; Kulasingam V
    Cancer Epidemiol Biomarkers Prev; 2016 Sep; 25(9):1333-40. PubMed ID: 27448593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rediscovery of the Anti-Pancreatic Antibodies and Evaluation of their Prognostic Value in a Prospective Clinical Cohort of Crohn's Patients: The Importance of Specific Target Antigens [GP2 and CUZD1].
    Papp M; Sipeki N; Tornai T; Altorjay I; Norman GL; Shums Z; Roggenbuck D; Fechner K; Stöcker W; Antal-Szalmas P; Veres G; Lakatos PL
    J Crohns Colitis; 2015 Aug; 9(8):659-68. PubMed ID: 25968583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers.
    Xu Y; Shen Z; Wiper DW; Wu M; Morton RE; Elson P; Kennedy AW; Belinson J; Markman M; Casey G
    JAMA; 1998 Aug; 280(8):719-23. PubMed ID: 9728644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The levels of soluble cMET ectodomain in the blood of patients with ovarian cancer are an independent prognostic biomarker.
    Klotz DM; Link T; Goeckenjan M; Wimberger P; Kuhlmann JD
    Mol Oncol; 2021 Sep; 15(9):2491-2503. PubMed ID: 33690968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.
    Hamed EO; Ahmed H; Sedeek OB; Mohammed AM; Abd-Alla AA; Abdel Ghaffar HM
    Diagn Pathol; 2013 Jan; 8():11. PubMed ID: 23343214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Moore LE; Pfeiffer RM; Zhang Z; Lu KH; Fung ET; Bast RC
    Cancer; 2012 Jan; 118(1):91-100. PubMed ID: 21717433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of monoclonal antibodies and development of an immunofluorometric assay for the detection of CUZD1 in tissues and biological fluids.
    Farkona S; Soosaipillai A; Filippou P; Korbakis D; Serra S; Rückert F; Diamandis EP; Blasutig IM
    Clin Biochem; 2017 Dec; 50(18):1168-1174. PubMed ID: 28746862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of HE4 and TTR for diagnosis of ovarian cancer: Comparison with CA-125.
    Zheng X; Chen S; Li L; Liu X; Liu X; Dai S; Zhang P; Lu H; Lin Z; Yu Y; Li G
    J Gynecol Obstet Hum Reprod; 2018 Jun; 47(6):227-230. PubMed ID: 29609043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High serum levels of follistatin in patients with ovarian cancer.
    Ren P; Chen FF; Liu HY; Cui XL; Sun Y; Guan JL; Liu ZH; Liu JG; Wang YN
    J Int Med Res; 2012; 40(3):877-86. PubMed ID: 22906260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.
    Hurteau JA; Woolas RP; Jacobs IJ; Oram DC; Kurman CC; Rubin LA; Nelson DL; Berchuck A; Bast RC; Mills GB
    Cancer; 1995 Nov; 76(9):1615-20. PubMed ID: 8635066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.